The Effect of Eszopiclone on the Arousal Threshold in Sleep Apnea Syndrome

Completed · Early Phase 1 · Has a placebo group

Conditions studied: Obstructive Sleep Apnea

In brief

The purpose of this study is to find out whether taking eszopiclone (Lunesta) changes the breathing effort required to briefly wake people with obstructive sleep apnea from sleep (respiratory arousal threshold). We would like to see if taking eszopiclone can reduce the severity of obstructive sleep apnea in some people (those that have a low respiratory arousal threshold; i.e. wake up easily to respiratory stimuli).

Key facts

Study ID

NCT01102270

Run by

Brigham and Women's Hospital

People needed

17

Starts

2009-01-01

Expected to finish

2010-05-01

Last updated by the study team

2017-04-18

Who can join

Age: 18 and older, up to 64. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• 18-64 years old
• Untreated obstructive sleep apnea

You may not qualify if…

• Nadir SaO2 <70% on a baseline PSG
• Medications known to affect either sleep, breathing or muscle activity
• Major co-morbidities apart from sleep apnea
• Allergy to lidocaine, oxymetazoline HCl, or eszopiclone
• Women who are pregnant

Where it is running

• Brigham and Women's Hospital, Division of Sleep Medicine — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.